administered, nuclear receptor repertoire expressed by a cell, and the physical pairings of the receptors expressed. RAR/RXR heterodimers are non-permissive as RXR agonism alone is insufficient for inducing transcription, RAR ligands can solely increase transcription, and simultaneous RAR/RXR agonism results in robust, synergistic changes in gene expression. [5, 6] In contrast, permissive receptors are activated with RXR ligand alone and arise when RXR members dimerize with non-RAR nuclear receptors such as PPARs. As retinoids embody agents capable of prompting changes in gene expression, the exploitation of RA and other structural analogues for therapeutic purposes is extensive. [7] In particular, natural and synthetic vitamin A derivatives are noted for their clinical efficacy in multiple human cancers including leukaemia, breast, hormone-refractory prostate and lung. [8] In particular, the use of ATRA in the treatment of acute promyelocytic leukaemia is commonly referred to as a milestone in molecular-based cancer therapy. [9] However, the full clinical potential of retinoid-based
strategies has yet to be realized as toxicity and detrimental side effects hinder use. These limitations occur largely due to the supraphysiological doses required to achieve a desired therapeutic outcome. [10] This principle is exemplified by the use of Bexarotene (Targretin®),
an RXR selective agonist, in the treatment of cutaneous T-cell lymphoma (CTCL). CTCL is a heterogeneous group of skin-tropic T-cell malignancies that account for nearly 4 per cent of all non-Hodgkin lymphoma. [11, 12] Retinoids have been employed for over three decades to treat CTCL. Currently, Bexarotene is the only FDA-approved retinoid to treat CTCL at all stages. Zhang and colleagues identified
Bexarotene exposure culminates in CTCL cell apoptosis, [13] and this original mechanism has since been verified and expanded to include cell cycle growth arrest. [14, 15] However, the maximal therapeutic benefit of Bexarotene is offset by interrelated, adverse metabolic side effects namely, hyperlipidemia, hypercholesterolaemia and hypothyroidism. [16, 17] Metabolic complications likely arise as RXRs play a vital role in metabolic integration among tissues as RXRs pair with liver X receptor and thyroid hormone receptor. [18] Considering the average therapeutic serum concentration among patients is 10 μM, [19] activation of multiple RXR-containing nuclear receptors by Bexarotene is unavoidable. The severity of these unwanted side effects warrants administration of additional therapies or cessation of retinoid therapy. [20] In the light of the strong clinical promise of vitamin A derivatives, mechanistic studies merit investigation. As retinoid receptor activation likely accounts for both desired clinical outcomes and confounding side effects, identifying the receptor isotypes that transduce retinoid exposure into cellular responses is paramount for advancing retinoid-based therapies in CTCL.
| METHODS

| Cell culture
The human T leukaemia/lymphoma cell lines Jurkat and CCRFCEM and human cutaneous T-cell lymphoma lines HuT78, MJ and HuT102
were purchased from ATCC (Manassas, VA). SeAx and MyLa lines were the generous gift of Dr. Robert Gniadecki (University of Copenhagen). All cell lines were maintained in 5% CO 2 incubator with RPMI 1640 media supplemented with 1 mM sodium pyruvate, 10% (v/v) fetal bovine serum, 10 mM HEPES, 1% L-glutamine and 1%
penicillin-streptomycin. SeAx and HuT102 media also contained 10 U/mL of recombinant IL-2. 
| Reagents and chemicals
| Static cell adhesion
Assays were adapted from established protocols. [25] Ligands were immobilized at the desired concentrations on Immulon-2 HB microtiter wells (Thermo Scientific, Waltham, MA) in 0.1 M NaHCO 3 .
Non-specific adhesion was minimized by blocking wells with 2% 
| Chemotaxis
Directed migration was quantitated using 24-well hanging cell culture For each sample, 10 000 ungated events were acquired.
| Apoptosis
| Western Blot
Cell lysates were prepared with RIPA buffer containing protease inhibitors from Roche. Cell suspensions were sonicated for 15 minutes, and cell debris was pelleted. After BCA quantitation of supernatant, protein amounts indicated in the corresponding figure legends were loaded and separated under reducing conditions.
| BrdU cell proliferation
Cell proliferation was quantitated by BrdU cell proliferation assay kit from Millipore. Briefly, cells were seeded at 2×10 5 cell/mL in 100 μL/well in 96-well tissue culture plate. Retinoids were supplemented at 2× the final desired concentration in 100 μL/well of media.
BrdU was added 24 hours prior to harvesting. After cell fixation, diluted anti-BrdU monoclonal antibody was added 100 μL/well for 1 hours. Cells were washed again and incubated with 100 μL filtered peroxidase-conjugated goat anti-mouse IgG, for 30 minutes at room temperature. After washing, 100 μL/well TMB substrate was added and incubated for 30 minutes at room temperature in the dark. Plates were read at 450/550 nm.
| Quantitative RT-PCR
RNA was isolated from cells treated with or without 0.3 nM RARα/5 nM Bexarotene for 72 hours using RNeasy Plus Mini Kit (Qiagen). cDNAs were reverse-transcribed from 1 μg of RNA by Verso cDNA Synthesis Kit (ThermoFisher) and subjected to qPCR using iQ SYBER Green Supermix (Bio-Rad, Hercules, CA). Amplification and detection was performed using an iCycler IQ real-time PCR detection system. Primer optimization identified 60°C as ideal, and all amplifications were followed by melt-curve analysis. α4 upstream primer: Ct values were normalized to those of GAPDH. 
| Statistical analyses
| RESULTS
| RARα activity predominately drives integrin β7 expression and function in CTCL cells
An early cellular marker of CTCL response to retinoids entails the functional induction of the β7 integrin. [26] We sought to identify the receptor isotypes that transduce retinoid exposure into this initial CTCL response. The extensive conservation between all three RXR isotypes has confounded the generation of isotype selective agents. [27] Due to the paucity of RXR isotype selective reagents, our initial approach was to investigate which RAR isotype(s) contribute to the heightened β7 expression and function.
We first undertook studies with the MJ and HuT78 cell lines as these lines represent the two major variants of CTCL, mycosis fungoides and Sézary syndrome, that account for over 70% of total CTCLs. [28, 29] 
| Concomitant activation of RARα and RXR receptors synergistically induces CTCL cell adhesion
RAR/RXR dual agonism can result in robust, synergistic changes in gene expression. [5, 6] As RAR activation alone yielded changes in integrin expression and function, we explored if CTCL cells exhibit retinoid receptor synergism. By utilizing Bexarotene alone or in combination with a RAR isotype selective agonist at nM levels, we demonstrate that RARα/RXR synergism potently induced β7-mediated adhesion within 24 hours of exposure ( Figure 2A ). This is in contrast to single agents or dual agonism of other RAR isotypes and Bexarotene ( Figure 2A ).
As synergism rapidly induced CTCL responses at low doses, we further explored the power of RARα/RXR synergism. Two CTCL cell lines, SeAx and MyLa, were previously reported to be insensitive to ATRA with respect to augmented β7 expression and function. [26] Notably, the combination of low dose RARα agonist (2×EC 50 ) and Bexarotene (100 nM) reversed retinoid insensitivity in both CTCL linages ( Figure 2B ). These results indicate that synergizing select retinoid receptors surmounts non-responsiveness that may occur in some refractory CTCL variants and attests to the potential impact of such combinatorial strategies. To further confirm that the robust response was due to genuine RAR/RXR agonism and not a spurious attribute of the synthetic retinoid Bexarotene, another RXR selective pan-agonist, SR11237, was utilized. SR11237 yielded the same result as Bexarotene validating the findings ( Figure 2C ).
RA induces α4β7 integrin expression through RARα-mediated transcriptional activation of the Itg-α4 gene in primary murine T cells. [30] Gene activation leads to increased α4-subunit abundance to promote dimerization with previously synthesized pools of β7. [31] To determine whether a similar mechanism of induction accounted for the current responses in human CTCL cells, the mRNA abundance 
| RARα/RXR coactivation promotes CTCL chemotaxis towards the gut-homing chemokine CCL25
Richardson and colleagues reported that Bexarotene potentially alleviates skin tropism of CTCL cells by dampening CCR4 expression. [32] However, a chief, natural role of vitamin A signalling is to establish and maintain mucosal immunity through populating mucosal structures. [33] Whether retinoids induce chemokine receptors associated with mucosal trafficking in addition to dampening skin trafficking receptors remains unknown.
As shown in Figure Directed migration towards 100 ng/mL of CCL25 was determined and displayed on the ordinate in arbitrary units (AU). (C) HuT78 or HuT102 cells were incubated with the vehicle DMSO, 1×EC 50 RARα agonist, 5 nM Bexarotene or combination of the two agonists. As described in (B), the relative extent of chemotaxis towards 100 ng/ mL of CCL25 was measured activation of RARα and RXR receptors at low doses prompted cell migration ( Figure 3C ).
| RARα/RXR synergism induces apoptosis and decreases proliferation of CTCL cells
We wanted to determine whether the same receptor pairs that induce the early adhesion and migratory changes in CTCL cells also prompt apoptosis and growth arrest. According to previous studies, Bexarotene-induced CTCL apoptosis and growth arrest require high doses (10 μM) and extended exposure times of at least 96 hours. [13, 14] In contrast, RARα/RXR coactivation achieved comparable levels of CTCL cell apoptosis with abbreviated times (48 hours) at lower dosage (5 nM Bexarotene) in MJ, HuT78 and MyLa cell lines ( Figure 4A ). 
| DISCUSSION
Discovery of retinoid nuclear receptors revolutionized the understanding of retinoid action in both normal and aberrant states. [3, 34, 35] These receptors comprise unique molecular drug targets for multiple cancers including CTCL. It is appreciated that skin-derived chemokine signals are pivotal in CTCL establishment, survival and expansion. [36] RARα/RXR recep- ported. [13, 14, 26, 32] This finding is of particular relevance considering the high doses of retinoids currently required to achieve clinical end points in CTCL.
Receptor synergism may also be a viable approach for refractory situations. [15] The CTCL-derived cell lines, SeAx and MyLa, are marginally responsive to completely resistant to single retinoid treatment, [26] but concomitant activation of RARα and RXR receptors overcame this insensitivity. In addition, the MJ cell line is resistant to apoptotic induction when exposed to Bexarotene alone. [14] However, synergism induced apoptosis with MJ cells. With respect to apoptotic protein markers, pharmacological doses of Bexarotene achieve changes of survivin in multiple CTCL lines but failed to decrease bcl-2 abundance. [14] In comparison, RARα/RXR synergism induced changes in both survivin and bcl-2 at a 2000-fold lower retinoid dose with a shorter exposure.
Investigations providing the molecular resolution necessary to attribute specific cellular responses to the activity of receptor subtypes are lacking. Preliminary reports attest to the potential clinical benefit of such tailored strategies. The antiproliferative ability of RARβ and RARγ agonists in premalignant and malignant human bronchial epithelial cells was enhanced upon RXR coactivation. [37] In addition, coactivation of RARγ and to a lesser extent RARα with RXRs induces apoptosis and inhibits proliferation of embryonic carcinoma cells. [38] However, these outcomes required μM levels of RAR and RXR agents. Here, we demonstrate that CTCL cells respond in at least four functional ways namely, adhesion, migration, apoptosis and proliferation to nM levels of retinoid when select receptors are costimulated.
Overall, the importance of the current findings is that (i) CTCL cellular responses were achieved with substantially lower dosages and shortened exposure time of retinoid compared to previous reports,
(ii) activation of the same receptor isotype or receptor pair accounted for multiple clinically relevant outcomes in CTCL including apoptosis and (iii) combinatorial activation of RARα and RXR receptors yielded detectable responses from refractory CTCL cells. The current findings suggest that Bexarotene therapy can be augmented with RARα agonism to induce synergistic receptor activation in CTCL. Isotypespecific activation coupled with receptor synergism described in the current work embodies a strategy, whereby a desired cellular response could be specified and amplified to such a degree that deleterious side effect associated with current retinoid dosing regimens might be circumvented.
